A multitude of VC funds, particularly those launched recently, have struggled to generate returns for their backers. However, Swiss investment company Redalpine stands out as a noteworthy exception. This distinction significantly contributed to the oversubscription of its latest $200 million fund aimed at early-stage investments, the organization has revealed.
The seventh installment of Redalpine’s funding initiatives, known as Redalpine Capital VII or RAC VII, is in full swing, supporting 15 to 20 startup ventures across Europe. So far, it has made nine lucrative investments, including in Proxima Fusion, a promising German nuclear technology startup.
“Following our initial fundraising, we immediately began to allocate the resources,” shared Michael Sidler, a founding member of Redalpine, in a discussion with TechCrunch. The deployment of funds is also aiding in establishing their new London office.
Redalpine’s history of delivering consistently high quartile returns has undeniably played a role in securing new investments. Managing over $1 billion in assets between its perpetual Summit Fund and various early-stage initiatives, the company has cultivated a vast network of limited partners. Many of these partners opted to invest further, impressed by the consistent performance. “Looking at the data from all seven of our funds, incorporating both older and newer ones, we’ve seen an average net return of about 25% per year over the past decade,” indicated Sidler.
Notably, some of these successes stem from Redalpine’s early investments in European fintech leaders like N26 and Taxfix. Yet, Redalpine’s investment strategy is closely aligned with evolving market trends. In 2006, Sidler and software entrepreneur Peter Niederhauser established Redalpine, with a vision centered on the intersection of software and science within Europe.
The area now often referred to as European deep tech, has gained attention from various investment bodies like Elaia, First Momentum, and IQ Capital, among others. The innovative output from Europe’s university startups is highly sought after, attracting attention from numerous limited partners.
Sidler highlighted Redalpine’s pioneering position in this domain, mentioning, “Our extensive networks across academia and the scientific domain, coupled with our team’s expertise spanning physics, medical sciences, materials science, and biotechnology, offer us a distinct edge. It’s a challenging task to build such a network, and having a team experienced in entrepreneurship, investing, and science is exceedingly rare,” he elaborated.
Despite the trends, RAC VII continues to maintain a sector-agnostic approach, exploring innovation opportunities across diverse fields like energy, health, and food. This strategy has afforded them a degree of resilience against market fluctuations. “Our eclectic focus has allowed us to realize exits from our portfolio even in tough market conditions like those experienced in 2022-2023. In 2024, we’ve already begun to see exits from our relatively young sixth fund and our Summit Fund,” Sidler commented.
Sidler, who has a PhD in molecular biology, exemplifies the firm’s deep scientific roots. “Half of our investment team comes with a background in science or engineering,” he noted. This expertise not only facilitates deep conversations with scientific entrepreneurs but also enhances operational support. Sidler highlighted the work with medtech startup Aktiia, where Redalpine’s general partner Daniel Graf has been instrumental in the company’s international expansion and played a key role in the appointment of their new CEO.
Although Graf is based in Silicon Valley, the opening of Redalpine’s new office in London, alongside its Berlin and Zurich locations, will streamline collaboration with the vibrant ecosystem there. According to Sidler, “The universities in and around London are producing increasingly fascinating deals.” One such deal is with the University of Cambridge spinout ExpressionEdits. Supported by RAC VII, the company is pioneering a computational gene editing platform that optimizes therapy effectiveness through AI, marking a significant technological advancement. “We are at a pivotal moment in technology development, driven by AI and biotechnological advancements,” Sidler told TechCrunch.
The article has been updated to reflect the accurate figure of ‘around 25%’ as provided by Redalpine.
Compiled by Techarena.au.
Fanpage: TechArena.au
Watch more about AI – Artificial Intelligence
